Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, aimed at attracting and retaining skilled personnel to drive the company’s long-term development goals. The schemes, subject to shareholder approval, are designed to align the interests of participants with shareholders through share ownership, and include conditional grants to key personnel, such as Dr. Zhu, to enhance the company’s value and stakeholder benefits.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biologic drugs. The company operates in the pharmaceutical industry, with a primary focus on creating innovative therapies to address unmet medical needs.
Average Trading Volume: 1,440,209
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.53B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.